SIETES :: 93135 citas

Resultados de la búsqueda por INTERLEUCINA 6 REFINAR BÚSQUEDA

1.

Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020:11 de julio. [Ref.ID 103688]

2.

Ritchie A, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?. Lancet 2020:24 de marzo. [Ref.ID 103571]

3.

Plushner SL. Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2008;42:1660-8. [Ref.ID 84614]

4.

Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JPT, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GDO, Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLOS Medicine 2008;5:78. [Ref.ID 82761]

5.

Neal B. Quantifying the importance of interleukin-6 for coronary heart disease. PLOS Medicine 2008;5:84. [Ref.ID 82756]

6.

Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trials. Lancet 2008;371:998-1006. [Ref.ID 82453]

7.

Smolen JS, Beauliez A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, for the OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. [Ref.ID 82452]

8.

Bongartz T. Tocilizumab for rheumatoid and juvenile idiopathic arthritis. Lancet 2008;371:961-2. [Ref.ID 82442]

9.

Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46. [Ref.ID 73379]

10.

McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakova O, Ford I, Capell HA, Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21. [Ref.ID 70480]

11.

Pradhan A D, Manson JE, Rossouw J E, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger M B, Ridker P M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. Prospective analysis from the Women's Health Initiative Observational Study. JAMA 2002;288:980-7. [Ref.ID 63099]

12.

Chikanza IC. Juvenile rheumatoid arthritis: therapeutic perspectives. Pediatr Drugs 2002;4:335-48. [Ref.ID 61901]

13.

Vorchheimer DA, Fuster V. Inflammatory markers in coronary artery disease. Let prevention douse the flames. JAMA 2001;286:2154-6. [Ref.ID 59343]

14.

Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. Effects of an early invasive or noninvasive strategy. JAMA 2001;286:2107-13. [Ref.ID 59338]

15.

Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L, Thomson A, Haskard D. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001;358:971-5. [Ref.ID 58555]

16.

Ridker P M. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet 2001;358:946-8. [Ref.ID 58550]

17.

Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51. [Ref.ID 57842]

18.

Reguart N, Gascón P. Uso actual y futuro de los factores de crecimiento hematopoyéticos. Med Clin (Barc) 2001;116:390-4. [Ref.ID 55786]

19.

Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16. [Ref.ID 55616]

20.

Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76. [Ref.ID 53965]